A SpaceX Falcon 9 rocket took off for the International Space Station carrying a smart laboratory developed by Israel’s SpacePharma. It will test Doxil from Israel’s Ayana to see its effect on cells in zero gravity. Doxil is the first … Continue reading →

The US FDA has approved Doxorubicin-HCI Liposomal Injection from Israel’s Ayana for the treatment of ovarian cancer, multiple myeloma, and Kaposi’s Sarcoma. The novel chemotherapy was developed by Hebrew University professor Yechezkel Barenholz (see here and here). https://www.jpost.com/health-and-wellness/generic-cancer-killing-israeli-drug-approved-for-marketing-by-fda-682430

This video of five major Israeli cancer detection and treatments was released to mark World Cancer Day on 4th Feb. They are Velcade for multiple myeloma; IceCure; RAD51 gene research; bone marrow transplants for leukemia; and Doxil’s delivery direct to … Continue reading →

Ruti Alon, co-chairman of this year’s IATI-Biomed Conference, highlighted that Israeli research is present in between 25% and 28% of the world’s successful biotech-based solutions.  E.g. Exelon for Alzheimer’s, Doxil for cancer and Copaxone for Multiple Sclerosis. http://www.timesofisrael.com/one-in-four-life-science-innovations-has-israeli-roots-says-expert/